| NCT ID | NCT04239703 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Kidney Transplant Rejection |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2019-12-01 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2019-12-01 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
Eligibility Criteria
Inclusion Criteria: * All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study. Exclusion Criteria: * Patients will be excluded from the study if they decline participation or are unable to give informed consent or multiple organ recipients.
Contact & Investigator
Philip F Halloran, MD, PhD
PRINCIPAL INVESTIGATOR
University of Alberta
Frequently Asked Questions
Who can join the NCT04239703 clinical trial?
This trial is open to participants of all sexes, studying Kidney Transplant Rejection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04239703 currently recruiting?
Yes, NCT04239703 is actively recruiting participants. Contact the research team at konrad@ualberta.ca for enrollment information.
Where is the NCT04239703 trial being conducted?
This trial is being conducted at Tampa, United States, Baltimore, United States, Baltimore, United States, Detroit, United States and 11 additional locations.
Who is sponsoring the NCT04239703 clinical trial?
NCT04239703 is sponsored by University of Alberta. The principal investigator is Philip F Halloran, MD, PhD at University of Alberta. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.